Your Messages Inbox
Your Article Summary
See Latest ArticlesKuvan Receives Priority Review Status From Health Canada
BioMarin, 06/11/09
BioMarin Pharmaceutical Inc. announced that it has received notice of priority review status for Kuvan as an oral treatment for patients with phenylketonuria from Health Canada. Priority review provides for a shortened submission review of 180 days versus the standard twelve months. BioMarin plans to file a marketing application for Kuvan in Canada in the third quarter of 2009, and with priority review status, a decision for marketing approval is expected in the first half of 2010.
Today in Popular Press...keeping you current
Receive free subspecialty "5-minute updates" via email
Two Delivery Systems Win Baldrige Award
HealthDataManagement, 12/18/09
A holiday message from AHA President and CEO Rich Umbdenstock
American Hospital Association News, 12/11/09
Nursing I.T. Award Deadline Dec. 2
HealthDataManagement, 12/10/09
Article Search
Sponsor